Presence of circulating anti-myosin antibodies in endomyocardial fibrosis
- PMID: 20422043
- PMCID: PMC2857887
- DOI: 10.1371/journal.pntd.0000661
Presence of circulating anti-myosin antibodies in endomyocardial fibrosis
Abstract
Background: Endomyocardial Fibrosis (EMF) is a tropical restrictive cardiomyopathy of unknown etiology with high prevalence in Sub-Saharan Africa, for which it is unclear whether the primary target of injury is the endocardial endothelium, the subendocardial fibroblast, the coronary microcirculation or the myocyte. In an attempt to explore the possibility of endocardial lesions being a result of an immune response against the myocyte we assessed the presence and frequency of circulating anti-myocardial antibodies in EMF patients.
Methodology/principal findings: EMF classification, assessment of severity and staging was based on echocardiography. We used sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) of myocardial proteins followed by western blotting to screen serum samples for antiheart antibodies G and M classes. The degree of serum reactivity was correlated with the severity and activity of EMF. We studied 56 EMF patients and 10 healthy controls. IgG reactivity against myocardial proteins was stronger and more frequent in patients with EMF when compared to controls (30/56; 53.6% vs. 1/10; 10%, respectively). IgM reactivity was weak in both groups, although higher in EMF patients (11/56; 19.6%) when compared to controls (n = 0). EMF patients showed greater frequency and reactivity of IgG antibodies against myocardial proteins of molecular weights 35 kD, 42 kD and 70 kD (p values <0.01, <0.01 and <0.05 respectively).
Conclusions: The presence of antibodies against myocardial proteins was demonstrated in a subset of EMF patients. These immune markers seem to be related with activity and might provide an adjunct tool for diagnosis and classification of EMF, therefore improving its management by identifying patients who may benefit from immunosuppressive therapy. Further research is needed to clarify the role of autoimmunity in the pathogenesis of EMF.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures


Similar articles
-
Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting.J Am Coll Cardiol. 1993 Nov 1;22(5):1378-84. doi: 10.1016/0735-1097(93)90546-d. J Am Coll Cardiol. 1993. PMID: 7901255
-
Association of pretransplantation antiheart antibodies with clinical course after heart transplantation.J Heart Lung Transplant. 1995 Jan-Feb;14(1 Pt 1):119-26. J Heart Lung Transplant. 1995. PMID: 7727460
-
Clinico-pathological evaluation of restrictive cardiomyopathy (endomyocardial fibrosis and idiopathic restrictive cardiomyopathy) in India.Eur J Heart Fail. 2004 Oct;6(6):723-9. doi: 10.1016/j.ejheart.2003.11.009. Eur J Heart Fail. 2004. PMID: 15542407
-
Comprehensive Assessment of Endomyocardial Fibrosis with Cardiac MRI: Morphology, Function, and Tissue Characterization.Radiographics. 2020 Mar-Apr;40(2):336-353. doi: 10.1148/rg.2020190148. Epub 2020 Jan 31. Radiographics. 2020. PMID: 32004118 Review.
-
Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives.Circulation. 2016 Jun 14;133(24):2503-15. doi: 10.1161/CIRCULATIONAHA.115.021178. Circulation. 2016. PMID: 27297343 Review.
Cited by
-
Endomyocardial involvement in asymptomatic sub-Saharan immigrants with helminth-related eosinophilia.PLoS Negl Trop Dis. 2017 Feb 24;11(2):e0005403. doi: 10.1371/journal.pntd.0005403. eCollection 2017 Feb. PLoS Negl Trop Dis. 2017. PMID: 28234952 Free PMC article.
-
The safety and efficacy of prednisolone in preventing reaccumulation of ascites among endomyocardial fibrosis patients in Uganda: a randomized clinical trial.BMC Res Notes. 2015 Dec 15;8:783. doi: 10.1186/s13104-015-1761-0. BMC Res Notes. 2015. PMID: 26666319 Free PMC article. Clinical Trial.
-
Endomyocardial fibrosis: A form of endemic restrictive cardiomyopathy.Glob Cardiol Sci Pract. 2012 Jul 17;2012(1):11. doi: 10.5339/gcsp.2012.11. eCollection 2012. Glob Cardiol Sci Pract. 2012. PMID: 25610842 Free PMC article. Review.
-
Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications.Biomedicines. 2023 Jan 1;11(1):107. doi: 10.3390/biomedicines11010107. Biomedicines. 2023. PMID: 36672615 Free PMC article. Review.
-
Endomyocardial fibrosis.Autops Case Rep. 2017 Sep 30;7(3):3-6. doi: 10.4322/acr.2017.024. eCollection 2017 Jul-Sep. Autops Case Rep. 2017. PMID: 29043203 Free PMC article. No abstract available.
References
-
- Buckman G, Ziegler J, Parry E. Endomyocardial fibrosis: still a mystery after 60 years. PloS Negl Trop Dis. 2008;2:e97. doi: 10.1371/journal.pntd.0000097. - DOI - PMC - PubMed
-
- Mocumbi AO, Yacoub S, Yacoub M. Neglected Tropical Cardiomyopathies: II. Endomyocardial Fibrosis: myocardial disease. Heart. 2008;94:384–90. - PubMed
-
- Kartha CC. Mini- review Endomyocardial fibrosis: a case for the tropical doctor. Cardiovasc Res. 1995;30:635–43. - PubMed
-
- Cherian KM, John TA, Abraham KA. Endomyocardial Fibrosis: clinical profile and role of surgery in management. Am Heart J. 1992;4:706–9. - PubMed
-
- Moraes F, Lapa C, Hazin S, Tenorio E, Gomes C, et al. Surgery for endomyocardial fibrosis revisited. Eur J Cardio-Thorac Surg. 1999;15:309–313. - PubMed